iDose TR implant administration in an office-based eye clinic

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, single-arm, open-label study evaluates the safety of delivering the travoprost intracameral implant (iDose TR) in an office-based surgery environment for adults with open-angle glaucoma or ocular hypertension. Participants receive a one-time 75 µg iDose TR implant and are followed to monitor adverse events and tolerability. The trial does not include a comparison group and focuses on real-world feasibility in an outpatient setting. It is sponsored by Glaukos Corporation with a dedicated investigational site in Austin, Texas. Eligibility requires a diagnosis of OAG or OHT and excludes prior iDose TR exposure or conditions that could confound implantation safety.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of Open angle glaucoma (OAG) or ocular hypertension (OHT)

Exclusion Criteria:

* Prior administration of iDose TR or administration of an investigational intracameral implant in the study eye
* Active ocular infection or inflammation
* History of hypersensitivity to travoprost or implant components
* Recent ocular surgery
* Uncontrolled systemic disease
* Any condition preventing safe implantation

Where it's running

• Glaukos Investigative Site
  Austin, Texas, United States Recruiting

Study contacts

• Study coordinator: Study Director
• Email: ClinicalResearch@glaukos.com
• Phone: 949-739-8749

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Direct (non-contact) laser versus standard selective laser for treating glaucoma

  This test compares a newer non-contact laser (DSLT) with the standard SLT to see if it lowers eye pressure just as well in adults with open-angle glaucoma or ocular hypertension.

  Recruiting Medical University of South Carolina · Charleston, South Carolina · NCT07408154

• Pregabalin eye drops vs timolol eye drops for open-angle glaucoma or ocular hypertension

  A doctor-led study tests whether pregabalin eye drops (TB0001) work as well as timolol eye drops to lower eye pressure in adults with glaucoma or high eye pressure.

  Recruiting at 3 sites Phase 2 Tavo Biotherapeutics · Glendale, California and 2 other locations · NCT07913074

• Eye drops Rhopressa vs Timolol to protect nerve cells in glaucoma

  In adults with open-angle glaucoma, this study tests whether Rhopressa helps preserve retinal nerve cells better than Timolol while both lower eye pressure.

  Recruiting Phase 4 Indiana University · Bloomington, Indiana · NCT07847073

• Brillouin hydration mapping to study cornea health

  Researchers test a Brillouin microscope to see if it can measure corneal water content in healthy people and those with eye conditions.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT07780890

• REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension

  This study tests REGN22530 in adults with POAG or ocular hypertension to see if it can lower eye pressure and what kind of side effects it may have.

  Recruiting Phase 1/2 Regeneron Pharmaceuticals · Deerfield Beach, Florida · NCT07675824

• Updated inserter for the 75 mcg Travoprost intracameral implant

  This study will see if the new G2-TRIO inserter reliably and safely delivers the 75 mcg Travoprost intracameral implant in adults with open-angle glaucoma or ocular hypertension.

  Recruiting Glaukos Corporation · Kenosha, Wisconsin · NCT07400926

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.